Skip to main content
. 2019 Aug 21;9(22):6485–6500. doi: 10.7150/thno.34429

Figure 4.

Figure 4

Intratumoral co-delivery of dox and immune adjuvants by NPs augments the levels of circulating CD3+, CD8+ and cancer antigen-specific CD8+ T cells. Quantification of CD3+, CD8+ and the HPV16 E7 tetramer specific T cells in blood at day 16 and at day 26 (8 and 16 days post-treatment) after treatment with intratumoral NP(dox+pIC+R848+MIP3α) as compared with free dox or PBS (mock control). (A&B) The levels of CD3+ and CD8+ T cells collected from blood of mice at day 16 (8 days after treatment) are depicted. n = 8 for NP(dox+pIC+R848+MIP3α), n = 8 for Dox and n = 5 for PBS. One representative out of two independent experiments. The differences between the groups are not statistically significant. (C) The levels of TM+ (cancer cell specific) CD3+CD8+ T cells collected from blood of mice at day 16 (8 days after treatment). n = 8 for NP(dox+pIC+R848+MIP3α), n = 8 for Dox and n = 5 for PBS. One representative out of two independent experiments. NP vs. dox (p=0.0351) and NP vs. PBS (p=0.0163). (D&E) The levels of CD3+ and CD8+ T cells collected from blood of mice at day 26 (18 days after treatment) are depicted. n = 8 for NP(dox+pIC+R848+MIP3α), n = 6 for Dox and n = 2 for PBS. One representative out of two independent experiments. The differences between the groups are not statistically significant. (F) The levels of TM+ (cancer cell specific) CD3+CD8+ T cells collected from blood of mice at day 26 (18 days after treatment). n = 8 for NP(dox+pIC+R848+MIP3α), n = 6 for Dox and n = 2 for PBS. One representative out of two independent experiments. The differences between the groups are not statistically significant. Statistics were calculated using a two-tailed Mann Whitney test. Statistical differences were considered significant at p < 0.05. * = p < 0.05; ** p = < 0.01; *** p < 0.001. All data are presented as mean ± SD. Abbreviations: TM: tetramer.